Key points are not available for this paper at this time.
Introduction 250 mg/dL was 36%, in extreme hyperglycemia 400 mg/dL was 5%, and in hypoglycemia 70 mg/dL was 1.3%. Hypoglycemic events (15+ min 70 mg/dL) occurred in 34% of enrollments (Fig 1B). In Fig 1C, glucose readings demonstrate a reduction of extreme deviations after enrollment. CGM was acceptable by patients and RN staff. Conclusion: This CGM as SOC protocol was feasible for inpatient T1D monitoring and management in a real-world hospital setting. Hypoglycemia and extreme hyperglycemia were infrequent. Disclosure S.R. Spierling Bagsic: None. S. Lohnes: Consultant; Dexcom, Inc. A.L. Fortmann: None. R. Belasco: None. H. Sandoval: None. A. Bastian: None. L. Talavera: None. D.J. Winkler: None. A. Philis-Tsimikas: Advisory Panel; Dexcom, Inc., Lilly Diabetes, Novo Nordisk, Sanofi, Medtronic, Bayer Inc. Funding Scripps Health and the David Winkler Endowment
Bagsic et al. (Fri,) studied this question.